Interleukin-17 and ischaemic stroke

Immunology. 2021 Feb;162(2):179-193. doi: 10.1111/imm.13265. Epub 2020 Oct 7.

Abstract

Interleukin-17 (IL-17) is a cytokine family that includes 6 members, IL-17A through IL-17F, most of them are reported to have pro-inflammatory role. Through binding to their receptors (IL-17Rs), IL-17 activates the intracellular signalling pathways to play an important role in autoimmune diseases, including rheumatoid arthritis (RA) and multiple sclerosis (MS). Ischaemic stroke is a complex pathophysiological process mainly caused by regional cerebral ischaemia. Inflammatory factors contribute to the physiological process of stroke that leads to poor prognosis. IL-17 plays a crucial role in promoting inflammatory response and inducing secondary injury in post-stroke. Though immune cells and inflammatory factors have been reported to be involved in the damage of stroke, the functions of IL-17 in this process need to be elucidated. This review focuses on the pathological modulation and the mechanism of IL-17 family in ischaemic stroke and seeking to provide new insights for future therapies.

Keywords: IL-17A; inflammation; interleukin-17 (IL-17); stroke; therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / immunology
  • Brain Ischemia / immunology
  • Humans
  • Interleukin-17 / immunology*
  • Ischemic Stroke / immunology*
  • Receptors, Interleukin-17 / immunology
  • Signal Transduction / immunology

Substances

  • Interleukin-17
  • Receptors, Interleukin-17